Salmeterol Xinafoate: An Analysis of Outcomes and Cost-Effectiveness Using a Primary Care Database

David Price; K. CARGILL; S. Wolfe; H. DARBY

doi:10.1016/s0954-6111(98)90232-3

Salmeterol Xinafoate: An Analysis of Outcomes and Cost-Effectiveness Using a Primary Care Database

David Price, K. CARGILL, S. Wolfe, H. DARBY

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Long-acting inhaled /&-agonists (LABS), used in conjunction with low-dose inhaled steroids, are a recommended alternative to high-dose inhaled steroids for asthmatics with persistent symptoms (1). There are, however, few published data regarding their cost-effectiveness. The drugs are relatively expensive and the aim of this study was to evaluateLAB cost-effectiveness in primary care, in terms of improved clinical outcomes (associated with reduced NHS costs) offsetting higher prescription costs. A controlled, retrospective, non-randomized analysis utilized the computerized Thorpewood Primary Care Database and compared clinical outcomes and asthma management costs 1 yr prior to and 1 yr after initiation of therapy with salmeterolxinafoate.

Original language	English
Pages (from-to)	1302-1304
Number of pages	3
Journal	Respiratory Medicine
Volume	92
DOIs	https://doi.org/10.1016/s0954-6111(98)90232-3
Publication status	Published - 1998

Bibliographical note

Acknowledgements
The authors wish to thank Leanne Rice of GlaxoWellcome U.K. for statistical analysis and GWUK for supporting the
writing of the manuscript.

Access to Document

10.1016/s0954-6111(98)90232-3Licence: Unspecified

Cite this

@article{ac263eadb4d9482287096469e0daa64b,

title = "Salmeterol Xinafoate: An Analysis of Outcomes and Cost-Effectiveness Using a Primary Care Database",

abstract = "Long-acting inhaled /&-agonists (LABS), used in conjunction with low-dose inhaled steroids, are a recommended alternative to high-dose inhaled steroids for asthmatics with persistent symptoms (1). There are, however, few published data regarding their cost-effectiveness. The drugs are relatively expensive and the aim of this study was to evaluateLAB cost-effectiveness in primary care, in terms of improved clinical outcomes (associated with reduced NHS costs) offsetting higher prescription costs. A controlled, retrospective, non-randomized analysis utilized the computerized Thorpewood Primary Care Database and compared clinical outcomes and asthma management costs 1 yr prior to and 1 yr after initiation of therapy with salmeterolxinafoate. ",

author = "David Price and K. CARGILL and S. Wolfe and H. DARBY",

note = "Acknowledgements The authors wish to thank Leanne Rice of GlaxoWellcome U.K. for statistical analysis and GWUK for supporting the writing of the manuscript. ",

year = "1998",

doi = "10.1016/s0954-6111(98)90232-3",

language = "English",

volume = "92",

pages = "1302--1304",

journal = "Respiratory Medicine",

issn = "0954-6111",

publisher = "Elsevier",

}

TY - JOUR

T1 - Salmeterol Xinafoate

T2 - An Analysis of Outcomes and Cost-Effectiveness Using a Primary Care Database

AU - Price, David

AU - CARGILL, K.

AU - Wolfe, S.

AU - DARBY, H.

N1 - Acknowledgements The authors wish to thank Leanne Rice of GlaxoWellcome U.K. for statistical analysis and GWUK for supporting the writing of the manuscript.

PY - 1998

Y1 - 1998

N2 - Long-acting inhaled /&-agonists (LABS), used in conjunction with low-dose inhaled steroids, are a recommended alternative to high-dose inhaled steroids for asthmatics with persistent symptoms (1). There are, however, few published data regarding their cost-effectiveness. The drugs are relatively expensive and the aim of this study was to evaluateLAB cost-effectiveness in primary care, in terms of improved clinical outcomes (associated with reduced NHS costs) offsetting higher prescription costs. A controlled, retrospective, non-randomized analysis utilized the computerized Thorpewood Primary Care Database and compared clinical outcomes and asthma management costs 1 yr prior to and 1 yr after initiation of therapy with salmeterolxinafoate.

AB - Long-acting inhaled /&-agonists (LABS), used in conjunction with low-dose inhaled steroids, are a recommended alternative to high-dose inhaled steroids for asthmatics with persistent symptoms (1). There are, however, few published data regarding their cost-effectiveness. The drugs are relatively expensive and the aim of this study was to evaluateLAB cost-effectiveness in primary care, in terms of improved clinical outcomes (associated with reduced NHS costs) offsetting higher prescription costs. A controlled, retrospective, non-randomized analysis utilized the computerized Thorpewood Primary Care Database and compared clinical outcomes and asthma management costs 1 yr prior to and 1 yr after initiation of therapy with salmeterolxinafoate.

U2 - 10.1016/s0954-6111(98)90232-3

DO - 10.1016/s0954-6111(98)90232-3

M3 - Article

C2 - 9926144

SN - 0954-6111

VL - 92

SP - 1302

EP - 1304

JO - Respiratory Medicine

JF - Respiratory Medicine

ER -

Salmeterol Xinafoate: An Analysis of Outcomes and Cost-Effectiveness Using a Primary Care Database

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this